Bolton G, Isaacs A (2018) Women’s experiences of cancer-related cognitive impairment, its impact on daily life and care received for it following treatment for breast cancer. Psychol Health Med 23(10):1261–1274
Henderson FM, Cross AJ, Baraniak AR (2019) ‘A new normal with chemobrain’: Experiences of the impact of chemotherapy-related cognitive deficits in long-term breast cancer survivors. Health Psychol Open 6(1):2055102919832234
Article PubMed PubMed Central Google Scholar
Jim HSL, Phillips KM, Chait S, Faul LA, Popa MA, Lee Y-H et al (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30(29):3578–3587
Article CAS PubMed PubMed Central Google Scholar
Fleming B, Edison P, Kenny L (2023) Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ 380:e071726
Article CAS PubMed Google Scholar
Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A (2013) Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology 22(7):1517–1527
Ando-Tanabe N, Iwamitsu Y, Kuranami M, Okazaki S, Yasuda H, Nakatani Y et al (2014) Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer 21(4):453–462
van Dam FSAM, Boogerd W, Schagen SB, Muller MJ, Droogleever Fortuyn ME, Evd Wall, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90(3):210–8
Wefel JS, Schagen SB (2012) Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 12(3):267–275
Article CAS PubMed Google Scholar
Amani O, Mazaheri MA, Moghani MM, Zarani F, Choolabi RH (2024) Chemotherapy-induced cognitive impairment in breast cancer survivors: a systematic review of studies from 2000 to 2021. Cancer Rep (Hoboken) 7(2):e1989
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20(2):485–493
Article CAS PubMed Google Scholar
Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML (2010) Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 119(2):366–369
de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ et al (2011) Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 32(8):1206–1219
van der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB (2018) Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Res 20(1):135
Article PubMed PubMed Central Google Scholar
Joly F, Castel H, Tron L, Lange M, Vardy J (2020) Potential effect of immunotherapy agents on cognitive function in cancer patients. J Natl Cancer Inst 112(2):123–127
Rogiers A, Leys C, De Cremer J, Awada G, Schembri A, Theuns P et al (2020) Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Support Care Cancer 28(7):3267–3278
Article CAS PubMed Google Scholar
Bartels F, Strönisch T, Farmer K, Rentzsch K, Kiecker F, Finke C (2019) Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol 30(5):823–829
Article CAS PubMed PubMed Central Google Scholar
Pullens MJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19(11):1127–1138
Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98(23):1742–1745
Article CAS PubMed Google Scholar
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356
Boomstra E, Walraven I, van der Ploeg IMC, Wouters M, van de Kamp MW, Dirven R et al (2024) Moving beyond barriers: a mixed-method study to develop evidence-based strategies to improve implementation of PROMs in clinical oncology care. Qual Life Res 34:173–188
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F et al (2020) Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core-an adaptive measure of core quality of life domains in oncology clinical practice and research. J Clin Epidemiol 117:117–125
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
Article CAS PubMed Google Scholar
Valentine TR, Weiss DM, Jones JA, Andersen BL (2019) Construct validity of PROMIS® Cognitive Function in cancer patients and noncancer controls. Health Psychol 38(5):351–358
Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS et al (2014) Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol 67(7):811–820
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F et al (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1–8
Feenstra HEM, Murre JMJ, Vermeulen IE, Kieffer JM, Schagen SB (2018) Reliability and validity of a self-administered tool for online neuropsychological testing: the Amsterdam Cognition Scan. J Clin Exp Neuropsychol 40(3):253–273
Feenstra HE, Vermeulen IE, Murre JM, Schagen SB (2018) Online self-administered cognitive testing using the Amsterdam Cognition Scan: establishing psychometric properties and normative data. J Med Internet Res 20(5):e192
Article PubMed PubMed Central Google Scholar
Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708
Ingraham LJ, Aiken CB (1996) An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 10(1):120
Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Münzel K (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9):1905–1913
Article CAS PubMed Google Scholar
Lim CYS, He S, Shaw J, Dhillon HM (2022) Cancer-related cognitive impairment: a mixed methods evaluation of a standard factsheet. Support Care Cancer 30(3):2375–2385
Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D et al (2017) Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol 35(2):217–225
Damholdt M, Mehlsen M, O’Toole M, Andreasen R, Pedersen A, Zachariae R (2016) Web-based cognitive training for breast cancer survivors with cognit
Comments (0)